[go: up one dir, main page]

WO2024220947A3 - Cibles épigénétiques pour améliorer l'immunothérapie anticancéreuse - Google Patents

Cibles épigénétiques pour améliorer l'immunothérapie anticancéreuse Download PDF

Info

Publication number
WO2024220947A3
WO2024220947A3 PCT/US2024/025594 US2024025594W WO2024220947A3 WO 2024220947 A3 WO2024220947 A3 WO 2024220947A3 US 2024025594 W US2024025594 W US 2024025594W WO 2024220947 A3 WO2024220947 A3 WO 2024220947A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer immunotherapy
enhancing cancer
epigenetic targets
compositions
epigenetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/025594
Other languages
English (en)
Other versions
WO2024220947A2 (fr
Inventor
Charles A. Gersbach
Sean MCCUTCHEON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of WO2024220947A2 publication Critical patent/WO2024220947A2/fr
Publication of WO2024220947A3 publication Critical patent/WO2024220947A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La divulgation concerne des compositions et des méthodes de modulation de lymphocytes T. Par exemple, les compositions et les procédés peuvent être utilisés pour accroître des lymphocytes T de mémoire. Les compositions et procédés peuvent être utilisés en combinaison avec une thérapie adoptive à lymphocytes T (ACT) pour améliorer l'ACT.
PCT/US2024/025594 2023-04-21 2024-04-19 Cibles épigénétiques pour améliorer l'immunothérapie anticancéreuse Pending WO2024220947A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363497688P 2023-04-21 2023-04-21
US63/497,688 2023-04-21
US202363498755P 2023-04-27 2023-04-27
US63/498,755 2023-04-27

Publications (2)

Publication Number Publication Date
WO2024220947A2 WO2024220947A2 (fr) 2024-10-24
WO2024220947A3 true WO2024220947A3 (fr) 2024-12-26

Family

ID=93153439

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/025594 Pending WO2024220947A2 (fr) 2023-04-21 2024-04-19 Cibles épigénétiques pour améliorer l'immunothérapie anticancéreuse

Country Status (1)

Country Link
WO (1) WO2024220947A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017180915A2 (fr) 2016-04-13 2017-10-19 Duke University Répresseurs à base de crispr/cas9 pour inactiver des cibles géniques in vivo et procédés d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021076744A1 (fr) * 2019-10-15 2021-04-22 The Regents Of The University Of California Cibles géniques pour agir sur le comportement des lymphocytes t
US20220244244A1 (en) * 2019-06-21 2022-08-04 Function Oncology, Inc. A genetic pharmacopeia for comprehensive functional profiling of human cancers
US20220249626A1 (en) * 2021-02-05 2022-08-11 Christiana Care Health Services, Inc. Methods of and compositions for reducing gene expression and/or activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220244244A1 (en) * 2019-06-21 2022-08-04 Function Oncology, Inc. A genetic pharmacopeia for comprehensive functional profiling of human cancers
WO2021076744A1 (fr) * 2019-10-15 2021-04-22 The Regents Of The University Of California Cibles géniques pour agir sur le comportement des lymphocytes t
US20220249626A1 (en) * 2021-02-05 2022-08-11 Christiana Care Health Services, Inc. Methods of and compositions for reducing gene expression and/or activity

Also Published As

Publication number Publication date
WO2024220947A2 (fr) 2024-10-24

Similar Documents

Publication Publication Date Title
WO2023164671A3 (fr) Compositions et méthodes d'édition d'épigénome pour améliorer une thérapie par lymphocytes t
WO2021034696A8 (fr) Cellules électrochimiques comprenant des espèces contenant un groupe thiol
WO2021108717A3 (fr) Systèmes et procédés pour l'évaluation d'édition hors cible indépendante de cas9 d'acides nucléiques
WO2020107002A3 (fr) Procédés d'amplification d'un sous-ensemble de cellules tueuses naturelles (nk) et compositions et procédés associés
MX2022007575A (es) Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos.
EP2003196A3 (fr) Compositions et procédés de diagnostic et de traitement des cancers
WO2020082046A3 (fr) Compositions et procédés d'expression du facteur ix
BR112013000822A2 (pt) método e método de duas etapas para a produção de uma população de células exterminadoras naturais (nk) ativadas, população de células nk ativadas e método para suprimir a proliferação de células tumorais
WO2024064642A3 (fr) Compositions, systèmes et méthodes de modulation de fonction de lymphocyte t
WO2006135886A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer
WO2024220947A3 (fr) Cibles épigénétiques pour améliorer l'immunothérapie anticancéreuse
WO2022129637A8 (fr) Polypeptides de recrutement de lymphocytes t basés sur la réactivité tcr alpha/bêta
CA3207182A1 (fr) Therapie par lymphocytes t
WO2023288007A9 (fr) Multiplication de cellules tueuses naturelles à mémoire
WO2020132027A3 (fr) Production acellulaire d'allulose
WO2022047222A3 (fr) Inactivation de protéines de cellules hôtes par le multiplexe de crispr/cas9
WO2020232141A3 (fr) Compositions et méthodes pour traiter l'épuisement des lymphocytes t
WO2003066663A3 (fr) Peptides utilises pour reconnaitre et cibler des tumeurs de cellules gliales
WO2022192249A3 (fr) Compositions et procédés d'évaluation et de traitement d'un dysfonctionnement des lymphocytes t
MX2023008485A (es) Anticuerpos inmunomoduladores y usos de estos.
WO2020243627A3 (fr) Inhibiteurs anti-crispr
AU2019356414A8 (en) Binding proteins specific for HA-1H and uses thereof
EP3927353A4 (fr) Méthode d'écotaxie et de rétention de lymphocytes t gammadelta, éventuellement avec des cellules tueuses naturelles, permettant de générer des compositions cellulaires destinées à être utilisées en thérapie
WO2022212947A8 (fr) Peptides cycliques spécifiques au kras, compositions et méthodes d'utilisation et de fabrication
WO2021197401A8 (fr) Polypeptide de liaison à l'antigène se liant à cd47, et son utilisation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2024793666

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24793666

Country of ref document: EP

Kind code of ref document: A2